On Tuesday 1 February, 2022, Oventus Chair Sue MacLeman, outlined the CEO succession plan, including the appointment of Mr John Cox, formerly President/COO as incoming CEO, and the transition of Dr. Chris Hart to the role of Executive Director and Chief Scientific Officer.
John Cox and Chris Hart also discussed the results for the quarter ended 31 December 2021 (FY22 Q2). During the quarter, O2Vent® sales rebounded, leading to a record revenue result for Oventus. This was achieved in tandem with strong increases in the sales pipeline, with the Direct to Consumer campaigns not only increasing active leads, but also increasing revenue per unit.
To view a recording of the webinar, please click below.
Leave a Reply